Abstract
The first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have brought substantial clinical benefit to patients with advanced non-small cell lung cancer (NSCLC) and sensitizing EGFR mutation. However, acquired resistance is inevitable since the vast majority of patients experience disease relapse within ~1-2 years. Osimertinib is a novel irreversible, covalent third-generation EGFR-TKI and potent inhibitor of EGFR T790M mutation, the most common mechanism of acquired resistance to first-generation EGFR-TKIs. Several trials have consistently demonstrated the superior clinical activity and safety of osimertinib in patients with advanced NSCLC and acquired EGFR T790M mutation after treatment with a first-generation EGFR-TKI. Recently, the efficacy of osimertinib in a first-line setting was demonstrated to be clearly superior to standard-first line treatment in patients with EGFR-mutant NSCLC regardless of T790M mutation status. Nevertheless, this advance, several unresolved issues of osimertinib should be emphasized including the molecular mechanisms of acquired resistance to osimertinib, the feasibility of testing EGFR T790M mutation from plasma circulating tumor DNA, its efficacy to...Continue Reading
Citations
Jul 4, 2019·Cancers·Eric Santoni-RugiuJens B Sørensen
Jun 12, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Osama M Al-Quteimat, Amer M Amer
Aug 21, 2020·Molecular and Cellular Biochemistry·Julia Matzenbacher Dos SantosHyesook Kim
Jul 18, 2020·Cancers·Margaux FresnaisRémi Longuespée
Jun 26, 2020·Patient Preference and Adherence·Ellen M JanssenJohn F P Bridges
Oct 1, 2019·British Journal of Cancer·Alessandro LeonettiMarcello Tiseo
Apr 10, 2019·Cancers·Hirotsugu HashimotoKentaro Inamura
Nov 12, 2020·Journal of Biomolecular Structure & Dynamics·Iqrar AhmadHarun Patel
Oct 24, 2020·International Journal of Molecular Sciences·Junghwa ChoiJaegal Shim
Oct 14, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Helena A YuDavid Planchard
Oct 4, 2020·Journal of the Chinese Medical Association : JCMA·Nalini Devi VerusingamMong-Lien Wang
Mar 18, 2021·The Clinical Respiratory Journal·Katsunori KagohashiHiroaki Satoh
May 21, 2021·BMC Pulmonary Medicine·Yang YangGuixing Xu
Jun 8, 2021·JCO Precision Oncology·M Zeeshan OzairNelson S Moss
Jul 30, 2021·Journal of Medicinal Chemistry·Matin ShaikhHarun Patel